{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:36:04Z","timestamp":1787686564873,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Strongbridge Biopharma plc, a wholly owned subsidiary of Xeris BioPharma Holdings Inc."},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study was undertaken to assess the unmet needs within the endogenous Cushing\u2019s syndrome (CS) care paradigm from the endocrinologist\u2019s perspective, including data abstracted from patient charts. The study evaluated endocrinologists\u2019 perceptions on burden of illness and treatment rationale along with the long-term clinical burden of CS, tolerability of CS treatments, and healthcare resource utilization for CS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective medical chart data from treated patients with a confirmed diagnosis of CS was abstracted using a cross-sectional survey to collect data from qualified endocrinologists. The survey included a case report form to capture patient medical chart data and a web-enabled questionnaire to capture practitioner-level data pertaining to endocrinologists\u2019 perceptions of disease burden, CS treatments, and treatment attributes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-nine endocrinologists abstracted data from 273 unique medical charts of patients with CS. Mean patient age was 46.5\u2009\u00b1\u200913.4\u00a0years, with a 60:40 (female:male) gender split. The mean duration of endogenous CS amongst patients was 4.1\u00a0years. Chart data indicated that patients experienced a high burden of comorbidities and symptoms, including fatigue, weight gain, and muscle weakness despite multi-modal treatment. When evaluating treatments for CS, endocrinologists rated improvement in health-related quality of life (HRQoL) as the most important treatment attribute (mean score\u2009=\u20097.8; on a scale of 1\u2009=\u2009Not at all important to 9\u2009=\u2009Extremely important). Surgical intervention was the modality endocrinologists were most satisfied with, but they agreed that there was a significant unmet treatment need for patients with CS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Endocrinologists recognized that patients with CS suffered from a debilitating condition with a high symptomatic and HRQoL burden and reported that improvement in HRQoL was the key treatment attribute influencing their treatment choices. This study highlights unmet needs for patients with CS. Patients with CS have a high rate of morbidity and comorbidity, even after treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-023-01371-y","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T14:02:10Z","timestamp":1704722530000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A medical chart audit to assess endocrinologist perceptions of the burden of endogenous Cushing\u2019s syndrome"],"prefix":"10.1007","volume":"27","author":[{"given":"Gabrielle","family":"Page-Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"issue":"9996","key":"1371_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A et al (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927","journal-title":"Lancet"},{"key":"1371_CR2","doi-asserted-by":"crossref","unstructured":"Hopkins RL, Leinung MC (2005) Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 34(2):371\u2013384, ix","DOI":"10.1016\/j.ecl.2005.01.013"},{"key":"1371_CR3","unstructured":"NORD (2021) Cushing syndrome. NORD. https:\/\/rarediseases.org\/rare-diseases\/cushing-syndrome\/"},{"issue":"2","key":"1371_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cen.14014","volume":"91","author":"S Wengander","year":"2019","unstructured":"Wengander S et al (2019) The incidence of endogenous Cushing\u2019s syndrome in the modern era. Clin Endocrinol (Oxf) 91(2):263\u2013270","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1371_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(1):101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"1371_CR6","doi-asserted-by":"publisher","first-page":"M33","DOI":"10.1530\/EJE-15-0464","volume":"173","author":"LK Nieman","year":"2015","unstructured":"Nieman LK (2015) Cushing\u2019s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33\u2013M38","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"1371_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000314224","volume":"92","author":"F Castinetti","year":"2010","unstructured":"Castinetti F, Conte-Devolx B, Brue T (2010) Medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 92(Suppl 1):125\u2013130","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1371_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MED.0b013e32835430bf","volume":"19","author":"F Castinetti","year":"2012","unstructured":"Castinetti F, Brue T, Conte-Devolx B (2012) The use of the glucocorticoid receptor antagonist mifepristone in Cushing\u2019s syndrome. Curr Opin Endocrinol Diabetes Obes 19(4):295\u2013299","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1371_CR9","first-page":"281","volume":"7","author":"ST Sharma","year":"2015","unstructured":"Sharma ST, Nieman LK, Feelders RA (2015) Cushing\u2019s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7:281\u2013293","journal-title":"Clin Epidemiol"},{"issue":"9","key":"1371_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-019-01128-7","volume":"79","author":"JM Hinojosa-Amaya","year":"2019","unstructured":"Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M (2019) Medical management of Cushing\u2019s syndrome: current and emerging treatments. Drugs 79(9):935\u2013956","journal-title":"Drugs"},{"issue":"4","key":"1371_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-023-01314-7","volume":"26","author":"G Page-Wilson","year":"2023","unstructured":"Page-Wilson G et al (2023) Evaluating the burden of endogenous Cushing\u2019s syndrome using a web-based questionnaire and validated patient-reported outcome measures. Pituitary 26(4):1\u201311","journal-title":"Pituitary"},{"issue":"7","key":"1371_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R et al (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4(7):611\u2013629","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1371_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10143-019-01134-z","volume":"43","author":"M Pertichetti","year":"2020","unstructured":"Pertichetti M et al (2020) Pituitary adenomas and neuropsychological status: a systematic literature review. Neurosurg Rev 43(4):1065\u20131078","journal-title":"Neurosurg Rev"},{"issue":"1","key":"1371_CR14","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-1101","volume":"173","author":"CD Andela","year":"2015","unstructured":"Andela CD et al (2015) Mechanisms in endocrinology: Cushing\u2019s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173(1):R1-14","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"1371_CR15","doi-asserted-by":"publisher","first-page":"dgaa291","DOI":"10.1210\/clinem\/dgaa291","volume":"105","author":"E Papakokkinou","year":"2020","unstructured":"Papakokkinou E et al (2020) Excess morbidity persists in patients with Cushing\u2019s disease during long-term remission: a Swedish nationwide study. J Clin Endocrinol Metab 105(8):dgaa291","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1371_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4158\/EP12247.OR","volume":"19","author":"AL Espinosa-de-Los-Monteros","year":"2013","unstructured":"Espinosa-de-Los-Monteros AL et al (2013) Persistence of Cushing\u2019s disease symptoms and comorbidities after surgical cure: a long-term, integral evaluation. Endocr Pract 19(2):252\u2013258","journal-title":"Endocr Pract"},{"issue":"2","key":"1371_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/eje.1.01953","volume":"153","author":"A Bhattacharyya","year":"2005","unstructured":"Bhattacharyya A et al (2005) Steroid withdrawal syndrome after successful treatment of Cushing\u2019s syndrome: a reminder. Eur J Endocrinol 153(2):207\u2013210","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1371_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1371_CR19","unstructured":"Freeman W, Weiss A, Heslin K (2018) Overview of U.S. hospital stays in 2016: variation by geographic region. Agency for Healthcare Research and Quality. https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb246-Geographic-Variation-Hospital-Stays.jsp"},{"key":"1371_CR20","unstructured":"Control, C.f.D. National Center for Health Statistics (2023) Ambulatory care use and physician office visits. https:\/\/www.cdc.gov\/nchs\/fastats\/physician-visits.htm"},{"issue":"4","key":"1371_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B et al (2017) Discordance between tender and swollen joint count as well as patient\u2019s and evaluator\u2019s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 76(4):708\u2013711","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1371_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13075-016-1004-3","volume":"18","author":"JS Smolen","year":"2016","unstructured":"Smolen JS et al (2016) Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther 18(1):114","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1371_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB et al (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23(2):140\u2013148","journal-title":"Pituitary"},{"issue":"1","key":"1371_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00000441-200607000-00004","volume":"332","author":"M Panda","year":"2006","unstructured":"Panda M et al (2006) The influence of discordance in pain assessment on the functional status of patients with chronic nonmalignant pain. Am J Med Sci 332(1):18\u201323","journal-title":"Am J Med Sci"},{"key":"1371_CR25","doi-asserted-by":"crossref","unstructured":"Page-Wilson GO, Maguire A, O'Hara M, Moloney S, Eliza G (2022) Patient-reported burden of illness in endogenous Cushing\u2019s syndrome","DOI":"10.1016\/j.eprac.2022.03.259"},{"key":"1371_CR26","doi-asserted-by":"crossref","unstructured":"Page-Wilson GO, Bhagyashree O, Silber A, Meyer J, O'Hara M, Geer E (2022) Physician perceptions on the treatment and health-related quality of life burden of endogenous Cushing\u2019s syndrome","DOI":"10.1016\/j.jval.2022.09.1451"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01371-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01371-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01371-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:33:08Z","timestamp":1712910788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01371-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01371-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"27 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Strongbridge Biopharma plc, a wholly-owned subsidiary of Xeris Biopharma Holdings, Inc. Gabrielle Page-Wilson, MD and Eliza B. Geer, MD were contracted by Strongbridge Biopharma, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc. to provide expert guidance for this study. Bhagyashree Oak, PhD, Abigail Silber, MPH, and Mathew O\u2019Hara, MBA are employees of Trinity Life Sciences, which was commissioned by Strongbridge Biopharma, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc. to conduct the current study. James Meyer, MBA, PharmD is an employee and shareholder of Xeris Pharmaceuticals, Inc. This research was funded in part through the NIH\/NCI Cancer Center Support Grant P30 CA008748.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This was an observational study conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. As this was not a randomized clinical trial, the study was not registered as such. The ADVARRA Institutional Review Board (Columbia, MD; ) has granted the study exemption from IRB oversight using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(2). The IRB also completed the necessary additional limited review considerations as set forth under the Revised Common Rule, 45 CFR 46.104(d).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study during the screening process and this was required to successfully enroll into the study. Participants were able to exit the study at any time or refuse to answer any questions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}